MMV & PARTNERS AT #TROPMED21

70th Annual Meeting

Defeating Malaria Together
Thursday 18 November

Symposium 7
Tackling the last mile of child mortality in Africa: Understanding and improving the case management of severe febrile illness

Symposium 35
Community delivery of Intermittent Preventive Treatment (IPTp): How it contributes to the goal of improved maternal and newborn health outcomes

Thursday 18 November

Poster Session A
0214 — In silico prioritization of library compounds for antimalarial drug development
0218 — The use of a humanized mouse model to assess antimalarial efficacy and identify optimal drug combinations
0280 — Introducing field digital data collection systems into seasonal malaria chemoprevention campaigns – lessons learnt and opportunities for robust evidence development

Friday 19 November

Symposium 57
Alan J. Magill Malaria Eradication Symposium

Symposium 65
Malaria: Drug treatment, resistance and clinical trials

Friday 19 November

Poster Session B
0665 — Multiple artemisinin-based combination therapies remain effective for Plasmodium falciparum malaria in Mali: A systematic review and meta-analysis
0717 — Gender determinants of Intermittent Preventive Treatment in Pregnancy uptake within malaria in pregnancy services in Cameroon and Kenya
0718 — Development and evaluation of video job-aids to support safe seasonal malaria chemoprevention delivery during the 2020 campaigns
0733 — Protecting adolescent girls against malaria— The need for adapted policies and health systems to benefit an underserved neglected population
0712 — Process evaluation for the implementation of artesunate rectal capsules as pre-referral intervention for severe malaria patients at community level in Madagascar
LB-5200 — Efficacy of pyronaridine-artenesunate against non-falciparum and mixed-species malaria: Post-hoc analysis of the CANTAM (Central Africa Network on Tuberculosis, HIV/AIDS and Malaria) real-world cohort event monitoring study

Saturday 20 November

Symposium 93
Intermittent Preventive Treatment for malaria in infants with sulfadoxine-pyrimethamine (SP-IPTi): Fit for purpose in 2021?

Symposium 102
Ex vivo assessment of drug susceptibility of the antimalarial drug pipeline

Saturday 20 November

Poster Session C
1145 — Assessing coverage of seasonal malaria chemoprevention in Ghana in 2020
Symposium 7

Thursday, 18 November, 14:00 PM – 15:45 PM CET, 08:00 AM – 09:45 AM EST

Tackling the last mile of child mortality in Africa: Understanding and improving the case management of severe febrile illness

Co-Chair: Aita Signorell, Swiss Tropical and Public Health Institute, Switzerland
Organizer: Christian Lengeler, Swiss Tropical and Public Health Institute, Switzerland

Speakers and topics:
- Saving lives from severe febrile illness: Large-scale experience from Nigeria
  Elizabeth Omoluabi, Akena Associates, Nigeria
- Saving lives from severe febrile illness: Large-scale experience from DR Congo
  Antoinette Tshefu, University of Kinshasa, Democratic Republic of the Congo
- Saving lives from severe febrile illness: Large-scale experience from Uganda
  Phyllis Awor, Makerere University, Uganda
- Panel: Implications of CARAMAL findings for policy making and upscaling of life-saving interventions
  Harriet Napier, Clinton Health Access Initiative, USA
  Silvia Schwarte, World Health Organization, Switzerland
  Valentina Buj, UNICEF, USA
Symposium 35

Community delivery of Intermittent Preventive Treatment: How it contributes to the goal of improved maternal and newborn health outcomes

Co-chair: Silvia Schwarte, World Health Organization, Switzerland
Organizer: Elaine Roman, Jhpiego, USA

Speakers and topics:

- An innovative community-based approach to increase the coverage of intermittent preventive treatment of malaria in pregnancy in four moderate to high transmission countries
  Odete Cossa, Jhpiego, USA

- Engaging ministries of health staff and national health management information systems to drive programmatic and technical quality while setting the stage for sustainability and scale up
  Herbert Onuoha, Jhpiego, USA

- An anthropological approach to assess barriers and facilitators to a community-based distribution of IPTp: Commonalities and variations across four SSA countries
  Ogonna Nwankwo, University of Calabar, Nigeria

- Results from household surveys in four SSA countries to measure the effects of community-based prevention of malaria on IPTp uptake and ANC attendance
  Clara Menendez, Barcelona Institute for Global Health, Spain

Symposium 57

Alan J. Magill Malaria Eradication Symposium: Keeping malaria eliminations on track: The successes and challenges on the pathway to eradication

Co-Chair: Philip Welkhoff, Bill & Melinda Gates Foundation, USA
Organizer: Michele Spring, Armed Forces Research Institute of Medical Sciences, USA

Speakers and topics:

- Welcome
  Julie Jacobson, Bridges to Development, USA

- Malaria elimination in the Americas: Progress, status and challenges
  Maria Grillet, Central University of Venezuela, Venezuela

- Keeping malaria eliminations on track: The successes and challenges on the pathway to eradication
  Rajesh Panjabi, President’s Malaria Initiative, USA

- Persevering through pandemics and re-imagining the path that will get us to zero
  Corine Karema, Quality and Equity Healthcare, Rwanda

- Presentation 4
  Pedro Alonso, World Health Organization, Switzerland
Symposium 65

Friday, 19 November, 19:45 PM – 21:30 PM CET, 13:45 PM – 15:30 PM EST

Malaria: Drug treatment, resistance and clinical trials

Co-chairs: Francisco-Javier Gamo, GlaxoSmithKline, UK
Melissa Rosenthal, University of Nebraska Medical Center, USA

Speakers and topics:

- Role of *Plasmodium falciparum* Kelch 13 protein mutations and falcipain 2a haplotypes in artemisinin resistance
  Faiza Siddiqui, University of South Florida, USA

- The importance of the parasite proteasome in artemisinin response
  Melissa Rosenthal, University of Nebraska Medical Center, USA

- Assessing feasibility of a strategy deploying multiple first-line artemisinin-based combination therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso
  Jean Moise Tanga Kabore, Groupe de Recherche Action en Santé (GRAS), Burkina Faso

- Measuring growth, resistance, and recovery after artemisinin treatment in a single semi-high-throughput assay
  Mackenzie Sievert, University of Notre Dame, USA

- The *Plasmodium falciparum* elongation Factor 2 inhibitor M5717 is efficacious against malaria liver-stage: A controlled liver-stage malaria infection study in healthy subjects
  Wilhelmina Bagchus, Merck KGaA, Germany

- A 2-part study to evaluate the asexual blood-stage antimalarial activity, and the transmission-blocking activity, of a single oral dose of tafenoquine in healthy subjects experimentally infected with *Plasmodium falciparum*
  Bridget Barber, QIMR Berghofer Medical Research Institute, Australia

- Rosiglitazone adjunctive therapy for children with severe malaria
  Rosauro Varo, Barcelona Institute for Global Health, Spain
Symposium 93
Saturday, 20 November, 14:00 PM – 15:45 PM CET, 08:00 AM – 09:45 AM EST

Intermittent Preventive Treatment for malaria in infants with sulfadoxine-pyrimethamine (SP-IPTi): Fit for purpose in 2021?
Co-chair: David Schellenberg, World Health Organization, Switzerland
Organizer: Roly Gosling, University of California, San Francisco, USA

Speakers and topics:
- Introduction
  David Schellenberg, World Health Organization, Switzerland
- Learnings from 3 years of SP-IPTi implementation in Sierra Leone and proposed adaptations that will be tested in Sierra Leone
  Clara Menendez, Barcelona Institute for Global Health, Spain
- The practicalities of choosing chemopreventive strategies across heterogenous country settings: The experience in Cameroon
  Dorothy Kah Fosah Achu, National Malaria Control Programme, Cameroon
- Addressing the evidence needs for SP-IPTi in Nigeria
  Olusola Oresanya, Malaria Consortium, UK
- Exploring the opportunities for adaptation of SP-IPTi to fit country needs of using a bottom-up co-creation design approach
  Sian Clarke, London School of Hygiene & Tropical Medicine, UK

Symposium 102
Saturday, 20 November, 18:45 PM – 20:30 PM CET, 12:45 PM – 14:30 PM EST

Ex vivo assessment of drug susceptibility of the antimalarial drug pipeline
Co-chair: Maëlle Duffey, Medicines for Malaria Venture, Switzerland
Organizer: Philip Rosenthal, University of California, San Francisco, USA

Speakers and topics:
- Genotype-phenotype associations for East African malaria parasites
  Oriana Kreutzfeld, University of California, San Francisco, USA
- Characterizing the drug susceptibility of malaria parasites in West Africa
  Laurent Dembelé, University of Bamako, Mali
- Characterizing Brazilian Plasmodium parasites and their response to various new drug candidates against malaria
  Caroline Aguiar, Universidade de São Paulo, Brazil
- Profiling new antimalarials against Cambodian parasites
  Camille Roesch, Institut Pasteur du Cambodge, Cambodia
Presenter:

0214  *In silico* prioritization of library compounds for antimalarial drug development  
  **Silviane A. Miruka**, Kenya Medical Research Institute, Kenya

0218  The use of a humanized mouse model to assess antimalarial efficacy and identify optimal drug combinations  
  **Iñigo Angulo-Barturen**, The Art of Discovery, Spain

0280  Introducing field digital data collection systems into seasonal malaria chemoprevention campaigns – Lessons learnt and opportunities for robust evidence development  
  **Abena Poku-Awuku**, Medicines for Malaria Venture, Switzerland
Programme

Poster Session B

Friday, 19 November, 18:00 PM – 19:30 PM CET, Noon – 13:30 PM EST

Presenter:

0665  Multiple artemisinin-based combination therapies remain effective for *Plasmodium falciparum* malaria in Mali: A systematic review and meta-analysis
  Fatoumata O Maiga, University of Sciences, Techniques and Technologies of Bamako, Mali

0712  Process evaluation for the implementation of artesunate rectal capsules as pre-referral intervention for severe malaria patients at community level in Madagascar
  Arsene Ratsimbasoa, University of Antananarivo, Madagascar

0717  Gender determinants of Intermittent Preventive Treatment in Pregnancy uptake within malaria in pregnancy services in Cameroon and Kenya
  Elizabeth Arlotti-Parish, President’s Malaria Initiative Impact Malaria project, USA

0718  Development and evaluation of video job-aids to support safe seasonal malaria chemoprevention delivery during the 2020 campaigns
  Susana Scott, London School of Hygiene and Tropical Medicine, UK

0733  Protecting adolescent girls against malaria– The need for adapted policies and health systems to benefit an underserved neglected population
  Abena Poku-Awuku, Medicines for Malaria Venture, Switzerland

LB-5200  Efficacy of pyronaridine-artesunate against non-*falciparum* and mixed-species malaria: Post-hoc analysis of the CANTAM (Central Africa Network on Tuberculosis, HIV/AIDS and Malaria) real-world cohort event monitoring study
  Stephan Duparc, Medicines for Malaria Venture, Switzerland
**Poster Session C**

**Saturday, 20 November, 17:00 PM – 18:30 PM CET, 11:00 AM – 12:30 PM EST**

**Presenter:**

**1145** Assessing coverage of seasonal malaria chemoprevention in Ghana in 2020  
**George Adu**, National Malaria Control Programme, Ghana

**Photos:**  
Emmanuelle Maseruka for MMV (pp 1, 3, 7 and 9); Daniel San Martin for MMV (pp 5 and 8)